Funds raised will be used to demonstrate clinical validation and proof-of-concept in t(4;14) multiple myeloma with KTX-1001 monotherapy and KTX-1001 combination regimens with existing standard-of-care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results